Cabaletta Bio, Inc. (CABA) stock
CABANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.02−0.09 (-8.11%)
Close on Nov 17, 2026Market cap $172.94MP/E –Yield –
Cabaletta Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cabaletta Bio's operating income for the twelve months ending Jun 30, 2026 was -$185.52M. For fiscal 2025 it was -$172.24M. The highest annual figure on record is -$6.19M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$172.24M | – |
| FY2024 | Dec 31, 2024 | -$125.14M | – |
| FY2023 | Dec 31, 2023 | -$74.66M | – |
| FY2022 | Dec 31, 2022 | -$54.14M | – |
| FY2021 | Dec 31, 2021 | -$46.31M | – |
| FY2020 | Dec 31, 2020 | -$33.83M | – |
| FY2019 | Dec 31, 2019 | -$18.68M | – |
| FY2018 | Dec 31, 2018 | -$6.19M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$52.02M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$42.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$46.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -$45.91M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.14M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.79M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.05M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.28M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.15M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.67M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.96M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.00M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.15M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.71M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.33M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.42M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.90M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.86M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.03M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.80M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.99M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.07M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.08M | – |
See a number that looks wrong?